Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …

Diagnostic molecular images, obtained by positron emission tomography (PET), have
successfully functioned as sensitive tools for detecting and monitoring the treatment of …

Zirconium-89-labeled monoclonal antibodies and other large macromolecules such as
nanoparticles hold great promise as positron emission tomography imaging agents. In …

Actinium-225 (225Ac) is one of the most promising radionuclides for targeted alpha therapy
(TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles …

Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid
malignancies, however, its use for solid malignancies remains a challenge. The putative …

Positron emission tomography (PET) and single-photon emission computed tomography
(SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to …

Despite the remarkable clinical successes of immune checkpoint inhibitors (ICIs) in various
advanced cancers, response is still limited to a subset of patients that generally exhibit …

Objectives 89 Zr-labelled proteins are gaining importance in clinical research in a variety of
diseases. To date, no clinical study has been reported that utilizes an automated approach …

The synthesis of radioimmunoconjugates via the stochastic attachment of bifunctional
chelators to lysines can yield heterogeneous products with suboptimal in vitro and in vivo …

Purpose: We recently identified CD46 as a novel therapeutic target in prostate cancer. In this
study, we developed a CD46-targeted PET radiopharmaceutical,[89Zr] DFO-YS5, and …